Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting
March 20 2024 - 10:27AM
Business Wire
Schr�dinger, Inc. (Nasdaq: SDGR), whose physics-based
computational platform is transforming the way therapeutics and
materials are discovered, today presented the discovery of
SGR-1505, its MALT1 inhibitor, during the First Time Disclosure
Session at the American Chemical Society (ACS) Spring 2024 Meeting.
SGR-1505 is being evaluated in a Phase 1 dose-escalation study in
patients with relapsed/refractory B-cell malignancies.
The oral presentation provided an overview of how Schr�dinger
leveraged its computational approaches at scale to discover
SGR-1505. Schr�dinger’s platform enabled vast exploration of
chemical space, triaging 8.2 billion compounds, synthesizing 78 of
the most promising molecules in the lead series, and identifying
SGR-1505 as the company’s development candidate in approximately 10
months. Reaching a development candidate can take three to six
years and typically involves synthesizing up to 5,000 molecules per
program.
“Designing the optimal molecule is a tremendous multi-parameter
optimization challenge that requires balancing many key
properties,” stated Aleksey Gerasyuto, Ph.D., head of medicinal
chemistry at Schr�dinger. “One of our goals in this program was to
address the limitations reported with other MALT1 inhibitors. By
leveraging our computational platform, our cross-functional team
simultaneously and rapidly optimized key drug-like properties and
designed several distinct chemical series, ultimately selecting
SGR-1505 as our development candidate.”
“We believe SGR-1505 has the potential to be a best-in-class
compound. The preclinical profile of SGR-1505, coupled with
positive data from our recently completed Phase 1 study in healthy
subjects, further increases our conviction about our MALT1
program,” said Margaret Dugan, M.D., chief medical officer at
Schr�dinger. “Our Phase 1 study in patients with
relapsed/refractory B-cell lymphomas is progressing well, and we
look forward to reporting initial data from the study in late 2024
or 2025.”
SGR-1505 Clinical Studies
Schr�dinger is conducting a Phase 1 dose-escalation study in
patients with relapsed/refractory B-cell lymphomas to evaluate the
safety, pharmacokinetics, pharmacodynamics and preliminary signals
of therapeutic activity of SGR-1505 as a monotherapy. The study is
enrolling patients at multiple sites in the U.S. and Europe. Once
the recommended dose is determined, an expansion cohort is planned
to evaluate SGR-1505 in combination with other anti-cancer agents,
such as BTK and BCL-2 inhibitors, in patients with specific B-cell
malignancies.
Schr�dinger recently completed a Phase 1 study showing that
SGR-1505 was well tolerated in a Phase 1 study of 73 healthy
volunteers. No drug-related serious adverse events or dose limiting
toxicities were observed in the study. The data also confirmed
target engagement, with greater than 90 percent inhibition of IL-2
secretion in activated T cells, a pharmacodynamic goal of the
study.
About Schr�dinger
Schr�dinger is transforming the way therapeutics and materials
are discovered. Schr�dinger has pioneered a physics-based
computational platform that enables discovery of high-quality,
novel molecules for drug development and materials applications
more rapidly and at lower cost compared to traditional methods. The
software platform is licensed by biopharmaceutical and industrial
companies, academic institutions, and government laboratories
around the world. Schr�dinger’s multidisciplinary drug discovery
team also leverages the software platform to advance a portfolio of
collaborative and proprietary programs to address unmet medical
needs.
Founded in 1990, Schr�dinger has approximately 850 employees and
is engaged with customers and collaborators in more than 70
countries. To learn more, visit www.schrodinger.com, follow us on
LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995, including but not limited to those regarding the potential
advantages of our computational platform, our research and
development efforts for SGR-1505, the timing, progress, and results
of clinical trials of SGR-1505, the clinical potential and
favorable properties of SGR-1505, and the potential for SGR-1505 to
be used for the treatment of advanced B-cell lymphomas. Statements
including words such as “aim,” "anticipate," "believe,"
"contemplate," "continue," "could," "estimate," "expect," “goal,”
"intend," "may," "might," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and statements in
the future tense are forward-looking statements. These
forward-looking statements reflect our current views about our
plans, intentions, expectations, strategies and prospects, which
are based on the information currently available to us and on
assumptions we have made. Actual results may differ materially from
those described in the forward-looking statements and are subject
to a variety of assumptions, uncertainties, risks and factors that
are beyond our control, including the uncertainties inherent in
drug development and commercialization, such as the conduct of
research activities and the timing of and our ability to initiate
and complete preclinical studies and clinical trials, whether
results from preclinical studies and early clinical trials will be
predictive of results of later preclinical studies and clinical
trials, uncertainties associated with the regulatory review of
clinical trials and applications for marketing approvals, the
ability to retain and hire key personnel and other risks detailed
under the caption "Risk Factors" and elsewhere in our Securities
and Exchange Commission filings and reports, including our Annual
Report on Form 10-K for the fiscal year ended December 31, 2023,
filed with the Securities and Exchange Commission on February 28,
2024, as well as future filings and reports by us. Any
forward-looking statements contained in this press release speak
only as of the date hereof. Except as required by law, we undertake
no duty or obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events, changes in expectations or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240320912754/en/
Matthew Luchini (Investors) Schr�dinger, Inc.
matthew.luchini@schrodinger.com 917-719-0636
Allie Nicodemo (Media) Schr�dinger, Inc.
allie.nicodemo@schrodinger.com 617-356-2325
Schrodinger (NASDAQ:SDGR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Schrodinger (NASDAQ:SDGR)
Historical Stock Chart
From Jul 2023 to Jul 2024